Snapshot from Sep 17, 2026 at 07:00 UTC. For live data and tracking: View Live
Regulatory regulatory filing

FDA accepts Alvotech AVT80 biosimilar BLA

Analysis based on 10 articles · First reported Aug 31, 2026 · Last updated Aug 31, 2026

Sentiment
30
Attention
4
Articles
10
Market Impact
General
Live prominence charts, article sentiment distribution, and event development timeline available on the Ergen Dashboard

The FDA acceptance is a positive regulatory milestone for Alvogen, potentially strengthening its biosimilar pipeline and competitive position. It may also benefit Teva through commercialization rights, while increasing competitive pressure on the reference product Entyvio.

Biotechnology Pharmaceuticals

Alvogen announced that the United States — Food and Drug Administration (FDA) has accepted for review a Biologics License Application (BLA) for AVT80, a proposed interchangeable biosimilar to Entyvio (vedolizumab) for subcutaneous administration. AVT80 is developed and manufactured by Alvogen under a partnership with Sun Pharma, which will handle commercialization. The BLA submission is supported by analytical, pharmacokinetic, and immunogenicity data, including a pivotal pharmacokinetic study that met all primary endpoints. AVT80 complements AVT16, an intravenous biosimilar candidate whose BLA was accepted in May 2026. The European Union — European Medicines Agency has also validated a Marketing Authorization Application covering both candidates. If approved, AVT80 would expand biosimilar options for ulcerative colitis and Crohn's disease patients in the U.S.

70 Alvogen announced positive results
60 European Union — European Medicines Agency validated Marketing Authorization Application Alvogen
priv
Alvogen is the developer and manufacturer of AVT80; FDA acceptance advances its biosimilar program and could enhance its market prospects.
Importance 100.0 Sentiment 60.0
govactor
The FDA accepted the BLA for review, a key regulatory step; its decision will determine market entry.
Importance 80.0 Sentiment 0.0
stock
Teva is the commercialization partner for AVT80; the regulatory progress supports its biosimilar portfolio and potential revenue.
Importance 70.0 Sentiment 50.0
govactor
The EMA validated the Marketing Authorization Application for AVT16 and AVT80, supporting European regulatory progress.
Importance 40.0 Sentiment 0.0
per
Joseph McClellan, COO of Alvogen, commented on the milestone, representing the company's leadership.
Importance 20.0 Sentiment 0.0
subs
Takeda Pharmaceutical Company — Takeda Oncology owns the Entyvio trademark; the biosimilar could compete with its product.
Importance 10.0 Sentiment -10.0
per
Róbert Wessman is the founder of Alvogen; his role is foundational but not directly impacted by this event.
Importance 5.0 Sentiment 0.0
ERGEN INTELLIGENCE
Track this event live

Set up alerts, explore entity relationships, search across thousands of events, and build custom intelligence feeds.

Open Dashboard

About Ergen

Ergen is a news intelligence platform that converts raw news articles into structured data. It tracks events, entities, and the relationships between them, with sentiment and attention metrics derived from thousands of articles. Pages on this site are daily static snapshots from the platform's live database. For real-time tracking, search, and alerts, the full dashboard is at app.ergen.ai.